Alto Neuroscience Proposes Equity Plan Amendments to Include Pre-Funded Warrants, Increasing Future Dilution Potential

summarizeSummary

Alto Neuroscience filed its definitive proxy statement, proposing amendments to its equity incentive and employee stock purchase plans to include pre-funded warrants in the "evergreen" share reserve calculation, which will increase future dilution.

check_boxKey Events · Corporate Governance and Compliance · ANRO

• Equity Plan Amendments Proposed

  Shareholders will vote on amending the 2024 Equity Incentive Plan and 2024 Employee Stock Purchase Plan.

• Expanded Evergreen Provision

  The amendments will include shares issuable from pre-funded warrants in the calculation for automatic annual increases to the share reserves of both equity plans. This follows the recent $120 million private placement that included 3.1 million pre-funded warrants.

• Increased Dilution Potential

  This change will lead to a larger pool of shares available for future equity awards and employee stock purchases, increasing potential dilution for existing shareholders. The additional shares from the evergreen feature are estimated to be approximately 1.1% of current outstanding shares annually.

• Board Expansion

  The Board of Directors was expanded from six to seven members, as agreed upon in the recent private placement.

auto_awesomeAnalysis · ANRO · Life Sciences

This definitive proxy statement outlines proposals for the upcoming annual meeting, most notably amendments to the 2024 Equity Incentive Plan and 2024 Employee Stock Purchase Plan. These amendments expand the "evergreen" provisions to include shares issuable upon the exercise of pre-funded warrants in the annual share reserve calculation. This change, directly following a $120 million private placement that included such warrants (announced on 2026-03-16), will result in a larger pool of shares automatically added to the equity compensation plans each year, increasing potential future dilution for existing shareholders. The filing also notes the board's expansion from six to seven directors, a direct outcome of the recent private placement agreement.